A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (NSCLC)

被引：70

作者：

Lynch, Thomas J.

Patel, Taral

Dreisbach, Luke

McCleod, Michael

Heim, William J.

Robert, Hermann

Eugene, Paschold

Virginie, Pautret

Weber, Martin R.

Woytowitz, David

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Mid Ohio Oncol Hematol Inc, Columbus, OH USA

[3] Desert Hematol & Oncol Med Grp, Rancho Mirage, CA USA

[4] Florida Canc Specialists, Ft Myers, FL USA

[5] Assoc NE, Hematol & Oncol, Dunmore, PA USA

[6] Wellstar Canc Res Off, Marietta, GA USA

[7] Piedmont Hematol Oncol Assoc, Winston Salem, NC USA

[8] Bristol Myers Squibb Co, Braine lAlleud, Belgium

[9] Bristol Myers Squibb Co, Wallingford, CT USA

来源：

关键词：

D O I：

10.1097/01.JTO.0000283155.03863.e7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S340 / S341

页数：2